Design and Analysis of Phase I Clinical Trials
From MaRDI portal
Publication:3201544
DOI10.2307/2531693zbMath0715.62241OpenAlexW2054383376WikidataQ44888410 ScholiaQ44888410MaRDI QIDQ3201544
Publication date: 1989
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2531693
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Related Items (58)
A note on continual reassessment method ⋮ Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations ⋮ Continual Reassessment Method for Partial Ordering ⋮ Designs for Single- or Multiple-Agent Phase I Trials ⋮ Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment ⋮ SEQUENTIAL METHODS IN CLINICAL TRIALS* ⋮ Designs foe phase i cancer clinical trials with differentiation of graded toxicity ⋮ A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents ⋮ The role of minimal sets in dose finding studies ⋮ Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm ⋮ Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial ⋮ Sequential method of estimating the LD50 using a modified up-and-down rule ⋮ A new design of the continual reassessment method ⋮ Methodology and application of adaptive and sequential approaches in contemporary clinical trials ⋮ PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials ⋮ A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes ⋮ Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics ⋮ Performance Measures in Dose‐Finding Experiments ⋮ A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials ⋮ Unnamed Item ⋮ A continual reassessment method without undue risk of toxicity ⋮ Stochastic approximation and modern model-based designs for dose-finding clinical trials ⋮ Continual reassessment and related dose-finding designs ⋮ Approximate dynamic programming and its applications to the design of Phase I cancer trials ⋮ A modified Huber loss function for continual reassessment methods in clinical trials ⋮ A new look at evaluating MTD designs in cancer research ⋮ A semi-Markov model for patient progression through clinical trials ⋮ Bayesian phase I/II adaptively randomized oncology trials with combined drugs ⋮ Analyzing longitudinal count data from adaptive clinical trials: a weighted generalized quasi-likelihood approach ⋮ The adaptive accelerated biased coin design for phase I clinical trials ⋮ Design issues for generalized linear models: a review ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ On the consistency of the continual reassessment method with multiple toxicity constraints ⋮ Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent ⋮ Retrospective Analysis of Sequential Dose‐Finding Designs ⋮ A class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approaches ⋮ Design efficiency in dose finding studies ⋮ Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials ⋮ The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach ⋮ Group up-and-down designs for dose-finding ⋮ Theoretical study of the continual reassessment method ⋮ Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials ⋮ Incoherent dose-escalation in phase I trials using the escalation with overdose control approach ⋮ The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach ⋮ A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents ⋮ A Parallel Phase I/II Clinical Trial Design for Combination Therapies ⋮ Unifying CRM and EWOC designs for phase I cancer clinical trials ⋮ A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method ⋮ Dose-Finding with Two Agents in Phase I Oncology Trials ⋮ Optimal Bayesian-feasible dose escalation for cancer phase I trials ⋮ Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials ⋮ Operating characteristics of the standard phase I clinical trial design. ⋮ Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials ⋮ Optimal designs for dose-escalation trials and individual allocations in cohorts ⋮ A sequential design for maximizing the probability of a favourable response ⋮ Testing simultaneous hypotheses in pharmaceutical trials: a bayesian approach ⋮ Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios ⋮ A conversation with Nancy Flournoy
This page was built for publication: Design and Analysis of Phase I Clinical Trials
